跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 35,317 条关于
“ileal bile acid transport inhibitor”
全部
35,317
临床试验
20,170
药物
6,746
机构
79
资讯
8,322
12个月前
Ipsen's Bylvay Receives Japanese Approval for Rare Liver Disease PFIC, Offering First Non-Surgical Treatment Option
去年
Health Canada Approves Bylvay for Alagille Syndrome Treatment, Marking First Dual-Indication Rare Disease Therapy
去年
Odevixibat Demonstrates Favorable Safety Profile in Pediatric PFIC Patients
去年
Ipsen's Kayfanda (Odevixibat) Receives EU Approval for Cholestatic Pruritus in Alagille Syndrome
去年
Odevixibat Demonstrates Sustained Improvement in Pruritus and Bile Acid Levels in Rare Cholestatic Liver Diseases
去年
Odevixibat Demonstrates Sustained Improvement in Pruritus and Bile Acid Levels in PFIC and ALGS Patients
去年
Odevixibat Demonstrates Sustained Improvement in Itch and Bile Acid Levels in PFIC and ALGS Patients
去年
Bylvay Shows Sustained Improvement in Itch and Bile Acid Levels in Rare Cholestatic Liver Diseases
去年
Bylvay Demonstrates Sustained Improvement in Itch and Bile Acid Levels in PFIC and ALGS Patients
去年
Ipsen Secures Dual CHMP Approvals for Rare Liver Disease Treatments Following Regulatory Strategy Shift
第 1 页，共 833 页
上一页
下一页
